Monday, 31 August 2026European Markets

ALUMEXX N.V. Stock Over 10% Up So Far On Tuesday

Loading stream...

(VIANEWS) - Shares of ALUMEXX N.V. (AEX-Index: ALX.AS) jumped by a staggering 10.62% to €0.63 at 11:06 EST on Tuesday, following the last session's upward trend. AEX-Index is rising 0.36% to €761.20, following the last session's downward trend. This seems, up until now, a somewhat positive trend exchanging session today.

ALUMEXX N.V.'s last close was €0.57, 36.37% under its 52-week high of €0.89.

About ALUMEXX N.V.

Alumexx N.V. manufactures and sells scaffoldings, stairs, ladders, accessories, and tools for indoor or outdoor use in the Netherlands and internationally. The company was formerly known as Phelix N.V. and changed its name to Alumexx N.V. in January 2018. Alumexx N.V. was founded in 1991 and is based in Etten-Leur, the Netherlands.

Earnings Per Share

As for profitability, ALUMEXX N.V. has a trailing twelve months EPS of €0.02.

PE Ratio

ALUMEXX N.V. has a trailing twelve months price to earnings ratio of 31.25. Meaning, the purchaser of the share is investing €31.25 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.5%.

Yearly Top and Bottom Value

ALUMEXX N.V.'s stock is valued at €0.63 at 11:06 EST, way below its 52-week high of €0.89 and way above its 52-week low of €0.48.

More news about ALUMEXX N.V. (ALX.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com